Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China
@article{ATM79484,
author = {Yafei Shi and Wei Chen and Yujun Zhang and Mingming Bo and Chunyu Li and Mingyu Zhang and Guohui Li},
title = {Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China},
journal = {Annals of Translational Medicine},
volume = {9},
number = {18},
year = {2021},
keywords = {},
abstract = {},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/79484}
}